Literature DB >> 17513819

Proposal for the use of progression-free survival in unblinded randomized trials.

Boris Freidlin1, Edward L Korn, Sally Hunsberger, Robert Gray, Scott Saxman, Jo Anne Zujewski.   

Abstract

Progression-free survival is an attractive end point for clinical trials when an overall survival end point may be confounded by additional treatments administered after progression. When a trial is performed in an unblinded manner, however, there is the potential for bias between the treatment arms because of the subjective aspects of the progression end point. We discuss the magnitude of this potential bias and suggest methods for lessening it. We propose the carrying forward of any progression information to two designated time points for the statistical analysis for trials that are not blinded. This proposal, possibly combined with central review of progression scans for these two time points, essentially eliminates any bias, with little risk of major efficiency loss compared with using the reported progression times.

Entities:  

Mesh:

Year:  2007        PMID: 17513819     DOI: 10.1200/JCO.2006.09.6198

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  24 in total

1.  Blinded independent central review of the progression-free survival endpoint.

Authors:  Ohad Amit; Will Bushnell; Lori Dodd; Nancy Roach; Daniel Sargent
Journal:  Oncologist       Date:  2010

2.  Design Issues in Randomized Clinical Trials of Maintenance Therapies.

Authors:  Boris Freidlin; Richard F Little; Edward L Korn
Journal:  J Natl Cancer Inst       Date:  2015-08-18       Impact factor: 13.506

Review 3.  Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?

Authors:  Lori E Dodd; Edward L Korn; Boris Freidlin; C Carl Jaffe; Lawrence V Rubinstein; Janet Dancey; Margaret M Mooney
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

4.  Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.

Authors:  Thomas J Herzog; Deborah K Armstrong; Mark F Brady; Robert L Coleman; Mark H Einstein; Bradley J Monk; Robert S Mannel; J Tate Thigpen; Sharee A Umpierre; Jeannine A Villella; Ronald D Alvarez
Journal:  Gynecol Oncol       Date:  2013-11-15       Impact factor: 5.482

5.  A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.

Authors:  Carol Aghajanian; Virginia Filiaci; Don S Dizon; Jay W Carlson; Matthew A Powell; Angeles Alvarez Secord; Krishnansu S Tewari; David P Bender; David M O'Malley; Ashley Stuckey; JianJiong Gao; Fanny Dao; Robert A Soslow; Heather A Lankes; Kathleen Moore; Douglas A Levine
Journal:  Gynecol Oncol       Date:  2018-05-24       Impact factor: 5.482

6.  Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer.

Authors:  Yingwei Qi; Katie L Allen Ziegler; Shauna L Hillman; Mary W Redman; Steven E Schild; David R Gandara; Alex A Adjei; Sumithra J Mandrekar
Journal:  Cancer       Date:  2012-03-20       Impact factor: 6.860

7.  The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.

Authors:  Lesley Seymour; S Percy Ivy; Daniel Sargent; David Spriggs; Laurence Baker; Larry Rubinstein; Mark J Ratain; Michael Le Blanc; David Stewart; John Crowley; Susan Groshen; Jeffrey S Humphrey; Pamela West; Donald Berry
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

8.  Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer.

Authors:  S Gill; S Berry; J Biagi; C Butts; M Buyse; E Chen; D Jonker; C Mărginean; B Samson; J Stewart; M Thirlwell; R Wong; J A Maroun
Journal:  Curr Oncol       Date:  2011-10       Impact factor: 3.677

Review 9.  Randomized phase II designs.

Authors:  Larry Rubinstein; John Crowley; Percy Ivy; Michael Leblanc; Dan Sargent
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

10.  A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605).

Authors:  H Kunitoh; T Tamura; T Shibata; K Nakagawa; K Takeda; Y Nishiwaki; Y Osaki; K Noda; A Yokoyama; N Saijo
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.